Amanta Healthcare is currently trading at upper limit of Rs. 191.00, up by 3.70 points or 1.98% from its previous closing of Rs. 187.30 on the BSE.
The scrip opened at Rs. 191.00 and has touched a high and low of Rs. 191.00 and Rs. 191.00 respectively. So far 5045 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 205.10 on 24-Aug-2026 and a 52 week low of Rs. 93.10 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 191.00 and Rs. 183.50 respectively. The current market cap of the company is Rs. 741.64 crore.
The promoters holding in the company stood at 63.80%, while Institutions and Non-Institutions held 13.35% and 22.85% respectively.
Amanta Healthcare has commenced production at its new SteriPort facility situated at Kheda campus. SteriPort has unique features like absolute sterility, superior transparency and far more tensile strength. This enhances the container integrity by manifold. It’s two-port system ensures leakproof IV administration and medication. SteriPort also demonstrates superior compatibility with potent drugs especially in Onco and Intensive Care.
The new facility incorporates technological advancements and higher degree of automation primarily aimed at reduced human interference, enhanced quality assurance and patient safety. The brownfield facility is expected to scale up the operational and financial efficiency, resulting into EBITDA margin expansion.
Amanta Healthcare is engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with ABFS and ISBM technology.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.15 |
| Dr. Reddys Labs. | 1158.25 |
| Cipla | 1377.00 |
| Lupin | 2112.50 |
| Zydus Lifesciences | 1130.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: